September 25, 2015

In the latest on the Mylan bid for Perrigo, Mylan on Thursday released a statement about the Perrigo lawsuit filed in Israel on Thursday.

September 21, 2015

In July, Stichting Preferred Shares Mylan exercised its full call option on over 488,000,000 preferred shares in Mylan — a move aimed at fending off Teva’s since abandoned attempt at acquiring the pharmaceutical company.

September 18, 2015

Mylan on Friday launched its generic version of Lescol XL (fluvastatin sodium) extended-release tablets.

September 17, 2015
The company’s president, CEO and chairman Joseph Papa has issued a letter to shareholders recommending against tendering their shares to Mylan.
September 14, 2015

Mylan announced Monday that it had launched its generic version of Pfizer’s Unasyn (ampicillin and subactam) injection. 

September 14, 2015

The Perrigo offer notwithstanding, Mylan is committed and well-positioned to pursue the OTC segment independently given its global scale and capabilities, company says. 

September 8, 2015

Under the terms of the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share.

August 28, 2015

Mylan will now move forward with its plans to tender a formal offer directly to Perrigo’s shareholders. 

August 26, 2015

Mylan this week announced the launch of its generic version of Pfizer’s Zosyn (piperacillin and tazobactam) injection.

August 26, 2015

The National Association of Chain Drug Stores has announced the winners of its Total Store Expo Product Showcase. 

August 14, 2015

Mylan announced will continue to urge its shareholders to vote in favor of its proposed acquisition of Perrigo despite Institutional Shareholder Services’ recommendation against the deal in a recent report.

August 11, 2015

Three years after it launched its EpiPen4ASchools program, Mylan announced this week that it would continue through the 2015-2016 school year.

August 10, 2015

The Food and Drug Administration approved Mylan's Lidocaine Patch 5%, a generic version of Endo Pharmaceutical's Lidoderm.

August 6, 2015

Mylan on Wednesday announced the U.S. launch of its generic version of Nexium (esomeprazole magnesium delayed-release capsules) in 20- and 40-mg dosage strengths.

July 29, 2015

Mylan on Wednesday announced that it received unconditional clearance from the European Commission under the European Union Merger Regulation for its acquisition of Perrigo Co., an Irish international manufacturer of private-label over-the-counter pharmaceuticals.

July 27, 2015

In a move that will reshape the generic pharmaceuticals landscape, Teva announced Monday that it would be acquiring Allergan Generics for $40.5 billion. 

July 24, 2015

On Friday, Stichting Preferred Shares Mylan, an independent foundation established in the Netherlands, announced that it would exercise its full call option to purchase 488,388,431 preferred shares in Mylan.

July 15, 2015

A collection of eight consumer groups have written to Federal Trade Commission chair Edith Ramirez in opposition of the ongoing potential merger between pharmaceutical companies Teva and Mylan. 

July 14, 2015

Both Mylan and Dr. Reddy’s Laboratories have announced the launch of their generic version of dementia drug Namenda.

July 9, 2015

 Mylan announced Thursday that it had launched its generic version of Valeant’s Targretin (bexarotene) 75-mg capsules.

June 19, 2015

The move gives Teva standing in Dutch court, should they decide to pursue action against Mylan.

June 16, 2015

Mylan’s largest shareholder has promised to back the company’s bid to buy Perrigo, which would help fend off Teva’s $40 billion takeover offer.

June 3, 2015

Mylan announced on Tuesday that it had launched its generic version of Teva’s  Seasonique birth control.

May 26, 2015

Acquisition target Perrigo recently filed a complaint to Irish Takeover Panel regarding Mylan proposal.